Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus Prednisone for Initial Therapy of cGVHD
NCT00815919Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in chronic graft-versus-host disease (cGVHD), sponsored by Dana-Farber Cancer Institute. Started Dec 2008; status: completed.
02
Drugs
bortezomib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00815919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00815919.